Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : DENDRITE INTERNATIONAL (DRTE) -- Ignore unavailable to you. Want to Upgrade?

To: James Bowser who wrote (5)	4/22/1998 3:49:00 PM
From: Boplicity	Read Replies (1) \| Respond to of 40

A dead thread I love it. Bask in the following. DENDRITE INTERNATIONAL (DRTE) 32 1/8 +2 1/4. Dendrite's 1st qtr earnings report is an example of how the market should actually function. The company delivered better-than-expected earnings, issued a forecst for even stronger full year results, and the stock was rewarded an "appropriate" increase in market-cap. For the 1st qtr ending March 31, the supplier of enterprise-wide sales force effectiveness solutions for the pharmaceutical industry reported that it pulled itself from under $0.02 a share in red ink from the year-ago quarter to report a profit of $0.15 a share for the latest period. The bottom-line figure came in 3 cents, or 25%, above the First Call mean estimate of three analysts surveyed. The company also logged record revenues of $22.6 million, up 36% from the year-ago period. At the same time, the company announced it would be increasing its full-year profit goals to $0.83 to $0.85 a share, which is 6.4% to 9% above the the current First Call mean estimate of $0.78 a share. Following the release of strong Q1 results and the company's indication of robust full year prospects, BA Robertson Stephens stepped in with an increase in earnings estimates and a reiteration of its 9-12 month price target of $60 a share, fully 87% above the stock's current price. According to the firm, DRTE's revenues came in about $676,000 above forecast, gross margin rose to 57.7% from 45% vs its estimate of 53.6%, and Days Sales Outstanding (DSOs) dropped another 13 days to 83, "as DRTE's financials became impeccable." The firm raises its FY98 earnings forecast by 6 cents to $0.85 (P/E 38) and its FY99 forecast by 9 cents to $1.10 (P/E 29). With a Price-Earnings/Growth (PEG) of 0.83 (based on FY99 estimate), DRTE is one of the few high-octane software stocks that actually trades at a discount to its growth rate. Greg

To: James Bowser who wrote (5)	4/22/1998 3:59:00 PM
From: Boplicity	Respond to of 40

Well james since it's too soon to post to myself I'll post to again. Company Press Release Dendrite Reports Record First Quarter Results and Raises Full Year Profit Goal Revenue up 36 Percent from Prior Year; Extraordinary Demand Sustaining Momentum MORRISTOWN, N.J.--(BUSINESS WIRE)--April 21, 1998-- Dendrite International, Inc. (NASDAQ/ NMS:DRTE), the leading supplier of enterprise-wide sales force effectiveness solutions for the pharmaceutical industry, today announced record first quarter revenues of $22.6 million for the period ended March 31, 1998, up 36 percent from the $16.6 million first quarter of 1997. First quarter 1998 record net income was reported at $1.76 million, or $0.15 per share on a diluted basis, compared with a net loss of $266,000, or a loss of $0.02 per diluted share, for the first quarter of 1997. At the same time, the Company announced it would be increasing its full-year profit goals to $0.83 - $0.85. The Company believes there is strong momentum in the Q3 and Q4 periods and that, together with the very strong Q1, this indicates a significantly strengthened full-year outlook. Some of the Company's first quarter strength in revenue was derived from existing customers hastening implementation programs and expanding product development commitments originally scheduled to have spanned both the first and second quarter of 1998. ''Our record first quarter reflects extraordinary demand in the U.S., record sales in Japan, and continued penetration of the Consumer Packaged Goods (CPG) market. Major new business included Parke-Davis in the United States, several new accounts in the CPG division and an extension of a recent agreement with a major Japanese pharmaceutical firm to include support services and an additional sales division. Dendrite continues to exceed our expectations on a global scale,'' said John Bailye, CEO of Dendrite. ''Our decision to raise our full-year profit goals is a credit to our dedicated and experienced team, who helped us accelerate the very demanding implementation schedules that are the key elements of our first quarter success.'' ''In late 1996 and throughout 1997 we made substantial investments in our product development, operational infrastructure and sales organization. We're witnessing the handsome payoff in 1998 with new and expanded customer commitments to our combination of skills, information and tools which improves the effectiveness of our customers' sales forces,'' Bailye said. Dendrite customers represent the leaders of the pharmaceutical and CPG industries. These global organizations achieve competitive advantage through Dendrite-supported field forces using Dendrite software and knowledge to quickly capitalize on opportunities arising in rapidly changing markets. About Dendrite Over 40,000 sales representatives and their managers in over 150 major corporations in 17 countries rely on Dendrite for a uniquely tailored combination of tools, information and skills to help them adapt to change and improve their sales success. The Company uses its highly specialized industry knowledge to develop modular software products that enhance sales force effectiveness by leveraging massive amounts of data to create actionable information, direct sales activities and facilitate enterprise- wide communication. The products, combined with specifically tailored coaching and support services, focus sales representatives on improving their performance. With a global infrastructure as its foundation, Dendrite's commitment to unparalleled service has been the hallmark of the business and the basis of strong customer loyalty since the Company's inception. Dendrite has two major divisions: the Healthcare Division, which is the largest supplier of sales force effectiveness solutions to the global pharmaceutical industry; and the Consumer Business Division, which serves the over-the-counter drug, cosmetics and consumer packaged goods industries worldwide. Headquartered in Morristown, New Jersey, Dendrite employs over 650 people in 14 offices around the world. For more information, visit the Company's Web site: drte.com. Note: Dendrite is a registered trademark of Dendrite International, Inc. This press release may contain statements that, if they are not verifiable historical fact, may be viewed as forward-looking statements that could predict future events or outcomes with respect to Dendrite and its business. The predictions embodied in these statements will involve risks and uncertainties and, accordingly, Dendrite's actual results may differ significantly from the results discussed or implied in such forward-looking statements. Greg - -

To: James Bowser who wrote (5)	4/22/1998 4:02:00 PM
From: Boplicity	Respond to of 40

SOrry james there is more. Now the numbers, which look pretty good. Dendrite International, Inc. Consolidated Statement of Operations (in thousands except per share data) (unaudited) Three Months Ended March, 31 1998 % 1997 % Revenues: License fees $2,971 13.1 $1,094 6.6 Services 19,656 86.9 15,548 93.4 22,627 100.0 16,642 100.0 Cost of revenues: Cost of license fees 361 12.2 273 25.0 Cost of services 46.9 9,208 59.2 9,209 9,570 42.3 9,481 57.0 Gross margin 13,057 57.7 7,161 43.0 Operating expenses: Selling, general and 8,459 37.4 6,373 38.3 administrative Research and development 7.0 1,270 7.6 1,584 10,043 44.4 7,643 45.9 Operating income (loss) 3,014 13.3 (482) (2.9) Interest income 196 0.9 128 0.7 Other expense (321) (1.4) (57) (0.3) Income (loss) before income 2,889 12.8 (411) (2.5) taxes Income taxes 1,127 5.0 (145) (0.9) Net income (loss) $1,762 7.8 ($266) (1.6) Net income (loss) per share: Basic $0.16 ($0.02) Diluted $0.15 ($0.02) Shares used in computing net income (loss) per share: Basic 11,162 11,225 Diluted 11,950 11,225 Take note of that Gross Margin Increase. One has to love that. Greg